MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
DALLAS, Texas, November 21, 2011 /PRNewswire/ –
The report “Leukemia Therapeutics Market (Acute/Chronic Lymphocytic
Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global
Market Forecast (2010 – 2020)” analyzes and studies the major market
drivers, restraints, and opportunities in North America, & Europe.
Browse market data tables and in-depth TOC on Leukemia Therapeutics
Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia)
Pipeline Assessment & Global Market Forecast (2010 – 2020).
Early buyers will receive 10% customization on reports.
Leukemia is the cancer of the white blood cells or the bone marrow,
which occurs due to an abnormal increase in the count of white blood cells.
It is identified by the spread of the diseases (either acute or chronic),
and by the type of the blood cell that is affected (lymphocytic or
myelocytic). This type of cancer can again be categorized into acute
lymphoblastic leukemia (ALL), which accounts for about 12%, chronic
lymphocytic leukemia (CLL) which accounts for 35%, acute myelogenous
leukemia (AML) which accounts for 29%, and chronic myelogenous leukemia
(CML) which accounts for 11% of the total leukemia.
The leukemia therapeutics market [
] was valued at $6.3 billion in 2010 and is expected to reach
$11.3 billion by 2020 at a CAGR of 3.84% between 2015 and 2020. The market
was dominated by chronic myeloid leukemia in 2010. However, in 2020, the
market is expected to be equally dominated by acute lymphocytic leukemia and
chronic myeloid leukemia, with sales amounting to $3.91 billion and $3.58
According to WHO, leukemia is expected to be more prominent in the
developed world such as North America and European countries due to genetic
factor. The other causes such as environmental factor and radiation exposure
are also the causative factors of all the types of leukemia.
The U.S. dominates the leukemia drug market in North America with 62%
share; whereas Germany dominates the market of Europe with 31.05% share.
The major players in the market include F. Hoffmann-La Roche Ltd
(Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Novartis
International AG (Switzerland), Bristol-Myers Squibb (U.S.), Eisai Co. Ltd
(Japan), Biogen Idec (U.S.), ERYtech Pharma (France) Celgene Corporation
(U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Clavis Pharma (Norway),
and Pfizer Inc. (U.S.).
MarketsandMarkets is a global market research and consulting company
based in the U.S. We publish strategically analyzed market research reports
and serve as a business intelligence partner to Fortune 500 companies across
MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, energy and power, food and beverages, industrial automation,
medical, pharmaceuticals, semiconductor and electronics, and
telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence repository.
To know more about us and our reports, please visit our website
Contact: Mr. Rohan 7557 Rambler Road, Suite 727, Dallas, TX 75231 Tel: +1-888-6006-441 Email: firstname.lastname@example.org MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com http://twitter.com/marketsmarkets